Pharmaceutical Sector

Roche Plans a Takeover of Japan’s Chugai: Reports Surge Share Prices

Roche Plans a Takeover of Japan’s Chugai: Reports Surge Share PricesThere was a record rise in the shares of Chugai Pharmaceutical of Japan which was a result of reports that said Roche the Swiss drug maker is looking for an acquisition of the company.

On Monday stocks of Chugai increased by 20% or more in Tokyo trading.

Biologic Drug-Maker Amgen Plans to Trim 12 to 15 Percent Jobs

Biologic Drug-Maker Amgen Plans to Trim 12 to 15 Percent JobsAmgen Inc. the biologic drug-maker says that it plans to trim down its workforce all over the world by 12 to 15% along with closing of four of its sites. This decision came in spite of reporting a strong second-quarter result which beat the expectations of the Wall Street.

In a Restructuring Effort Allergan Plans to Cut 1,500 Jobs

In a Restructuring Effort Allergan Plans to Cut 1,500 JobsAllergan Inc. the maker of wrinkle removing Botox will be shedding off 13 percent of its workforce cutting down 1, 500 jobs and eliminating an extra 250 vacant posts in its bid to avoid an intimidating takeover from Valeant Pharmaceuticals International.

FDA approves Cubist Sivextro to treat skin infections

FDA approves Cubist Sivextro to treat skin infectionsSivextro, an antibacterial medication made to treat skin diseases, was affirmed for utilization on Friday, June 20.

Even with genuine diseases, for example, MRSA and strains of Streptococcus, this pill, otherwise called tedizolid phosphate, and others of its kind are an earnest need. Numerous past pills are progressively getting futile because of antimicrobial safety.

US conference to see AstraZeneca reveal diabetes trial results

US conference to see AstraZeneca reveal diabetes trial resultsAstrazeneca is to showcase its new diabetes solutions at a meeting this week, as it tries to persuade financial specialists that it can flourish freely in the wake of warding off takeover enthusiasm from US match Pfizer.

Injectable Asthma Drugs to Replace Traditional Inhalers

asthmaAsthma inhalers are bidding bye as injectable biotech asthma drugs have emerged as a much better treatment, especially for patients with severe asthma. They are effective in patients not benefitted by traditional inhalers. The injectable treatment for asthma has unleashed a race among rival pharmaceutical firms to establish a strong foothold in a new market worth a more than $7.5 billion.

Pages